520 related articles for article (PubMed ID: 31862474)
21. Chimeric Antigen Receptor-Redirected Regulatory T Cells Suppress Experimental Allergic Airway Inflammation, a Model of Asthma.
Skuljec J; Chmielewski M; Happle C; Habener A; Busse M; Abken H; Hansen G
Front Immunol; 2017; 8():1125. PubMed ID: 28955341
[TBL] [Abstract][Full Text] [Related]
22. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
Siegler EL; Wang P
Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
[TBL] [Abstract][Full Text] [Related]
23. Road testing new CAR design strategies in multiple myeloma.
Rana PS; Murphy EV; Kort J; Driscoll JJ
Front Immunol; 2022; 13():957157. PubMed ID: 36016950
[TBL] [Abstract][Full Text] [Related]
24. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
25. The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells.
Hughes-Parry HE; Cross RS; Jenkins MR
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31892219
[TBL] [Abstract][Full Text] [Related]
26. Immune modulation via T regulatory cell enhancement: Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases-An EAACI position paper of the Task Force on Immunopharmacology (TIPCO).
Roth-Walter F; Adcock IM; Benito-Villalvilla C; Bianchini R; Bjermer L; Boyman O; Caramori G; Cari L; Fan Chung K; Diamant Z; Eguiluz-Gracia I; Knol EF; Kolios A; Levi-Schaffer F; Nocentini G; Palomares O; Redegeld F; Van Esch B; Stellato C
Allergy; 2021 Jan; 76(1):90-113. PubMed ID: 32593226
[TBL] [Abstract][Full Text] [Related]
27. Unlocking the potential of Tregs: innovations in CAR technology.
Requejo Cier CJ; Valentini N; Lamarche C
Front Mol Biosci; 2023; 10():1267762. PubMed ID: 37900916
[TBL] [Abstract][Full Text] [Related]
28. Engineered T cells and their therapeutic applications in autoimmune diseases.
Bao L; Bo XC; Cao HW; Qian C; Wang Z; Li B
Zool Res; 2022 Mar; 43(2):150-165. PubMed ID: 35008131
[TBL] [Abstract][Full Text] [Related]
29. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
30. Advances and Challenges of CAR T Cells in Clinical Trials.
Holzinger A; Abken H
Recent Results Cancer Res; 2020; 214():93-128. PubMed ID: 31473850
[TBL] [Abstract][Full Text] [Related]
31. Effective Targeting of TAG72
Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
Front Immunol; 2018; 9():2268. PubMed ID: 30510550
[TBL] [Abstract][Full Text] [Related]
32. Chimeric antigen receptor therapy meets mRNA technology.
Wu J; Wu W; Zhou B; Li B
Trends Biotechnol; 2024 Feb; 42(2):228-240. PubMed ID: 37741706
[TBL] [Abstract][Full Text] [Related]
33. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
34. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C
Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176
[TBL] [Abstract][Full Text] [Related]
35. Challenges and new technologies in adoptive cell therapy.
Zhang P; Zhang G; Wan X
J Hematol Oncol; 2023 Aug; 16(1):97. PubMed ID: 37596653
[TBL] [Abstract][Full Text] [Related]
36. CAR-T Cell Therapy: From the Shop to Cancer Therapy.
Uscanga-Palomeque AC; Chávez-Escamilla AK; Alvizo-Báez CA; Saavedra-Alonso S; Terrazas-Armendáriz LD; Tamez-Guerra RS; Rodríguez-Padilla C; Alcocer-González JM
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958672
[TBL] [Abstract][Full Text] [Related]
37. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
Jindal V; Arora E; Gupta S
Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
[TBL] [Abstract][Full Text] [Related]
38. Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells.
Dawson NA; Lamarche C; Hoeppli RE; Bergqvist P; Fung VC; McIver E; Huang Q; Gillies J; Speck M; Orban PC; Bush JW; Mojibian M; Levings MK
JCI Insight; 2019 Mar; 4(6):. PubMed ID: 30753169
[TBL] [Abstract][Full Text] [Related]
39. Chimeric Antigen Receptor Structure and Manufacturing of Clinical Grade CAR Engineered Cells using Different Bioreactors.
Syed F; El Fakih R; Alahmari AD; Osman Ali AS; Aljurf M
Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):137-152. PubMed ID: 36395497
[TBL] [Abstract][Full Text] [Related]
40. The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy.
Liu D; Badeti S; Dotti G; Jiang JG; Wang H; Dermody J; Soteropoulos P; Streck D; Birge RB; Liu C
Cell Commun Signal; 2020 Aug; 18(1):134. PubMed ID: 32843053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
